CD16 Shedding in Monocyte Flow Cytometry: When Gating Misclassifies Cells

The preanalytical problem behind a familiar CD14/CD16 gate

Kwon, Shin and Ryu investigated why monocyte subset frequencies can change during common ex vivo immunological procedures. Their peer-reviewed paper in Frontiers in Immunology, published 13 October 2026 (DOI 10.3389/fimmu.2026.1886931), connects CD16 surface loss to ADAM17-dependent shedding. For a clinical flow cytometry reader, the point is immediate: a CD16-defined population can appear to disappear even while its constituent cells remain viable. An apparent classical, intermediate or nonclassical shift can reflect handling biology rather than an in vivo lineage redistribution.

The authors examined human PBMC preparations and sorted monocytes, measured phenotype after stimulation and used metalloproteinase inhibitors as a mechanistic intervention. They also reanalysed public single-cell resources. The study is an experimental immunology investigation, not a trial of an accredited clinical monocyte-subset assay. No universal diagnostic cutoff or specimen-stability claim follows from it.

What changed, and how large was the shift?

In the reported LPS stimulation experiments, a four-hour ex vivo interval was accompanied by an approximately 84–87% relative loss of the intermediate and nonclassical CD16-positive monocyte categories in PBMC analyses. Sorted CD16-positive cells showed roughly 68–77% lower surface CD16 after a similar incubation while viability remained substantially preserved (Figure 3, four donor experiments). The distinction matters: losing CD16 on a monocyte is not evidence that the monocyte died, switched developmental lineage or was absent from the original specimen.

The group compared pharmacological perturbations. The ADAM17 inhibitor TMI-005 (apratastat), and TAPI-1 in related conditions, mitigated phenotype loss under the tested stimulation protocols (Figure 5; six donors). The comparison supports a role for ADAM17-mediated ectodomain shedding. It does not establish that routine clinical samples should be treated with these inhibitors. ADAM17 acts on other substrates, and the paper discusses cytokine and solvent effects, including TNF-alpha behaviour that can change with inhibition.

Why flow gating alone cannot establish a biological transition

Most monocyte repartitioning strategies rely on CD14/CD16 boundaries. If CD16 is shed during isolation, warming or stimulation, a subset of formerly CD16-positive monocytes moves in fluorescence space. Conventional gating will then report a different distribution, even though no patient-level biological change has been demonstrated. A useful flow analysis preserves marker intensity distributions and the sample-handling context, not just the final percentages in three quadrants.

The appropriate response is not to designate CD16 as an unreliable biomarker in every clinical setting. Rather, the reportable measurand must name the specimen and conditions. Whole blood and isolated PBMCs may not produce equivalent ex vivo dynamics; one experiment's observation of relative whole-blood stability does not support a general eight-hour processing allowance. Cold chain, anticoagulant, cell isolation, stimulation cocktail, incubation time, compensation controls and antibody clone can all matter locally.

A focused assay-verification experiment

For an intended monocyte-subset assay, pair native whole-blood aliquots with the PBMC workflow actually used by the laboratory. Prespecify handling delays and temperatures. Track viable CD45-positive monocytes, absolute recovery, CD14 and CD16 fluorescence distributions, acquisition time and instrument setup, and compare with a zero-time reference. Test whether threshold movement, loss of total events or surface shedding dominates the observed shift. Repeat with realistic donors, not only high-level LPS challenge. Select allowable variation against the intended decision, not against an attractive published chart.

Do not confuse a research inhibitor-rescue experiment with a validated diagnostic remedy. A chemical inhibitor can preserve an epitope while modifying other cellular signals. If a laboratory were to introduce such treatment, its identity as part of the assay would demand independent assessment of effects on gating, other markers, viable-cell recovery and any functional endpoint. This CFCM proposal concerns methodological questions, not advice to alter a clinical test.

Daily Learning Pill — phenotype is partly a function of preparation

A downward shift in CD16 fluorescence can alter CD14/CD16 subset assignment while the same cells are still present. When a cytometry population moves, check the entire chain: cells sampled, preparation, epitope state, detector signal and gate. Reclassification is not the same as depletion.

Evidence boundary and further reading

Primary text reviewed: Introduction, methods for human PBMC preparation, stimulation and inhibition, results with figure descriptions and donor numbers, and Discussion. The study uses modest research donor Ns and mechanistic ex vivo conditions. It does not provide clinical reference intervals, multicentre reproducibility or IVDR validation. No published figure is reproduced; CFCM artwork is an original conceptual synthesis.

Read the peer-reviewed primary paper. Related CFCM education: why clinical panel decisions require explicit rules and validation. Explore further flow cytometry technical reviews at CFCM and join the newsletter using the site form.